1. The interplay between lung galectins and pro-fibrotic markers in post-COVID-19 fibrogenesis: A pilot study.
- Author
-
Oatis D, Balta C, Herman H, Ciceu A, Simon-Repolski E, Mihu AG, Lepre CC, Russo M, Trotta MC, D'Amico G, Casillo A, D'Amico M, and Hermenean A
- Subjects
- Humans, Male, Pilot Projects, Female, Middle Aged, Aged, Adult, Galectin 3 metabolism, Galectin 1 metabolism, Actins metabolism, Connective Tissue Growth Factor metabolism, Transforming Growth Factor beta metabolism, Blood Proteins, COVID-19 metabolism, COVID-19 pathology, COVID-19 complications, COVID-19 virology, Pulmonary Fibrosis metabolism, Pulmonary Fibrosis pathology, Biomarkers metabolism, Galectins metabolism, Bronchoalveolar Lavage Fluid chemistry, Lung metabolism, Lung pathology, SARS-CoV-2
- Abstract
Aims: COVID-19, caused by the SARS-CoV-2 virus, can lead to serious lung conditions, notably interstitial pulmonary fibrosis., Main Methods: Our study tracked the progression of fibrosis markers in serial bronchoalveolar lavage (BAL) measurements collected from 16 COVID-19 patients at 1, 3, and 6 months post-infection. Additionally, BAL samples from 10 healthy control subjects were included. Using RT-PCR, ELISA, and immunofluorescence, we monitored molecular markers of fibrosis and investigated the interplay between galectins-1 and -3 and key pro-fibrotic mediators., Key Findings: We found increased α-smooth muscle actin (αSMA)-positive macrophages and heightened levels of αSMA, TGFβ, and CTGF mRNA and proteins at six months compared to controls. Furthermore, galectin-1 and galectin-3 concentrations showed a time-dependent increase and correlated significantly with pro-fibrotic markers., Significance: These findings suggest that galectins contribute to fibrotic progression following COVID-19 and highlight their potential as therapeutic targets., Competing Interests: Declaration of competing interest The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper., (Copyright © 2024 The Authors. Published by Elsevier Inc. All rights reserved.)
- Published
- 2025
- Full Text
- View/download PDF